Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02355158 · ClinicalTrials.gov registry record · Phase 2
A Safety Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Painful Diabetic Neuropathy
A Phase 2 study, sponsored by BioDelivery Sciences International.
- Completed
- Registry status
- Phase 2
- Development phase
- 197
- Enrollment target
NCT02355158 is a Phase 2 study that has completed, run by BioDelivery Sciences International. The registered enrollment target is 197 participants.
The verdict
NCT02355158, a Phase 2 study, has completed, sponsored by BioDelivery Sciences International.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 197 participants
- Enrollment target
Study Summary
Study CLO-311 is a multicenter, open-label, single-arm study to assess the long-term use of Clonidine Gel in the treatment of pain associated with PDN. Subjects who have completed their 12-week participation in Study CLO-290 or Study CLO-310 are eligible to rollover into this study and receive active study drug in an open-label manner.
Interventions
- DRUG clonidine hydrochloride topical gel, 0.1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02355158
The ClinicalTrials.gov registry entry for NCT02355158 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioDelivery Sciences International, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which clonidine hydrochloride topical gel, 0.1% is the first listed.
NCT02355158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02355158 about?
NCT02355158 is a clinical study titled "A Safety Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Painful Diabetic Neuropathy". Study CLO-311 is a multicenter, open-label, single-arm study to assess the long-term use of Clonidine Gel in the treatment of pain associated with PDN. Subjects who have completed their 12-week participation in Study CLO-290 or Study CLO-310 are eligible to rollover into this study and receive activ...
What is the current status of trial NCT02355158?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 197 participants. The study started on 2014-06. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02355158?
The interventions under investigation include: clonidine hydrochloride topical gel, 0.1% (DRUG).
Who is sponsoring clinical trial NCT02355158?
This trial is sponsored by BioDelivery Sciences International, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.